|
ImmuPharma PLC - specialist drug discovery and development company - Says Avion Pharmaceuticals, its US partner for its Lupuzor lupus treatment, received a Type C Meeting confirmation from the US Food & Drug Administration. The London-listed company says statement of purpose, objectives and proposed agenda of the meeting have already been agreed on, as has the option to provide written responses, rather than face-to-face meetings. The FDA has agreed to provide a written response by August 29.
‘We applaud the quick turnaround from the FDA in respect to Avion's request for this Type C Meeting and pleased to note the FDA's confirmation that only a written response is required and no face to face meeting is needed,’ Chief Executive Tim McCarthy says.
Current stock price: 5.94 pence, up 12% Thursday
12-month change: down 31%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
